BioCryst Pharmaceuticals (BCRX) and Pharming Group (PHGUF) Head to Head Contrast
Posted by ABMN Staff on Mar 18th, 2018 // No Comments
BioCryst Pharmaceuticals (NASDAQ: BCRX) and Pharming Group (OTCMKTS:PHGUF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, analyst recommendations and risk.
Institutional & Insider Ownership
Get BioCryst Pharmaceuticals alerts:
91.7% of BioCryst Pharmaceuticals shares are held by institutional investors. 5.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares BioCryst Pharmaceuticals and Pharming Group’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets
BioCryst Pharmaceuticals -261.18% -106.53% -42.94%
Pharming Group -69.48% -259.69% -33.75%
Earnings and Valuation
This table compares BioCryst Pharmaceuticals and Pharming Group’s gross revenue, earnings per share and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioCryst Pharmaceuticals $25.19 million 21.02 -$65.78 million ($0.78) -6.88
Pharming Group $17.57 million 48.11 -$19.40 million ($0.11) -13.27
Pharming Group has lower revenue, but higher earnings than BioCryst Pharmaceuticals. Pharming Group is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and target prices for BioCryst Pharmaceuticals and Pharming Group, as provided by MarketBeat.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioCryst Pharmaceuticals 0 3 5 0 2.63
Pharming Group 0 0 2 0 3.00
BioCryst Pharmaceuticals currently has a consensus target price of $8.83, indicating a potential upside of 64.49%. Given BioCryst Pharmaceuticals’ higher probable upside, equities research analysts clearly believe BioCryst Pharmaceuticals is more favorable than Pharming Group.
Volatility & Risk
BioCryst Pharmaceuticals has a beta of 2.63, meaning that its stock price is 163% more volatile than the S&P 500. Comparatively, Pharming Group has a beta of 2.5, meaning that its stock price is 150% more volatile than the S&P 500.
Summary
BioCryst Pharmaceuticals beats Pharming Group on 8 of the 14 factors compared between the two stocks.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals logoBioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company’s drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.
About Pharming Group
Pharming Group logoPharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies. The Company’s products are aimed at treatments for genetic disorders and surgical and traumatic bleeding. Pharming’s technologies include novel transgenic platforms for the production of biopharmaceuticals, as well as technology and processes for the purification and formulation of these biopharmaceuticals. The Company’s commercial partners are: Santarus, Sobi, MegaPharm, Eczacibasi, Transmedic and Hyupjin. The Company operates worldwide. In March 2014, it announced downsizing of the Dutch operations following from strategic re-emphasis on collaborative development efforts and out-sourcing of non-core activities.